Bimagrumab (BYM338) — Research Compounds Library | RetatrutideCompare

Fully-human monoclonal antibody against activin type II receptors. Phase 2 RCT in obese T2D patients (NCT03005288) showed ~21% fat-mass loss and ~3.6% lean-mass gain over 48 weeks.